Asthma Clinical Trial
Official title:
Assessment of Safety, Tolerability, and Pharmacokinetics of Zileuton Injection in Patients With Asthma
The prevalence of asthma continues to increase. Despite the large number of available
therapies, many patients continue to require emergency deparment (ED) visits and intensive
therapy. However, ED visits continue to be a major contributor to the healthcare cost of
asthma treatment. In the United States alone, asthma is the 11th most common reason for ED
visits, with ED visits and hospitalizations accounting for almost 50% of the healthcare cost
for asthma. Additionally, while only 20% of asthmatics have had ED visits or
hospitalizations, these patients account for over 80% of the direct costs for asthma
treatment. Current National Asthma Education and Prevention Program (NAEPP) guidelines
regarding management of acute asthma exacerbations in the ED setting include: oxygenation
for most patients, inhaled short-acting β2-agonists and systemic corticosteroids.
Zileuton, a specific 5-lipoxygenase inhibitor, has been extensively studied in inflammatory
diseases such as asthma, which involve leukotrienes as mediators of inflammation. Zileuton
Immediate Release (IR) tablets (Zyflo®) were approved by the Food and Drug Administration
(FDA) in December 1996 for the prevention and treatment of asthma in adults and children 12
years of age and older. The results of the 2 pivotal studies in asthmatics with zileuton IR
tablets demonstrated that zileuton at a dose of 600 mg QID produced and maintained a lasting
improvement of lung function. In addition to the lasting effect of zileuton, an acute
bronchodilation (as early as 60 minutes) was observed after administration of the first 600
mg oral dose.
This acute bronchodilator effect may benefit patients during an acute exacerbation of asthma
when added to the usual care in the ED or clinic setting. Critical Therapeutics has
developed an injectable formulation of zileuton that will be explored for use in acute
asthma exacerbations. This initial study is intended to provide PK data, information on
safety and tolerability and some indication of pharmacologic activity as evidenced by lung
function changes. In an attempt to enhance the potential for observing effects on lung
function, only those patients with a demonstrated ability to respond by an increase in FEV1
of at least 10% within 3 hours after oral zileuton dosing will be enrolled.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|